NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses
NanoViricides(US:NNVC) Accessnewswire·2025-10-15 12:45公司临床开发策略 - 公司报告称一份分析师研究报告解释了其针对NV-387的双轨快速临床开发策略 [1] - 该策略旨在同时针对MPox以及所有呼吸道病毒感染 [1] - 目标呼吸道病毒感染包括流感、冠状病毒、呼吸道合胞病毒等 [1]